WO2013044865A1 - 含有并环的噁唑烷酮类抗菌素 - Google Patents
含有并环的噁唑烷酮类抗菌素 Download PDFInfo
- Publication number
- WO2013044865A1 WO2013044865A1 PCT/CN2012/082422 CN2012082422W WO2013044865A1 WO 2013044865 A1 WO2013044865 A1 WO 2013044865A1 CN 2012082422 W CN2012082422 W CN 2012082422W WO 2013044865 A1 WO2013044865 A1 WO 2013044865A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- ring
- methyl
- substituted
- Prior art date
Links
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title abstract description 8
- 239000003242 anti bacterial agent Substances 0.000 title abstract description 6
- 229940088710 antibiotic agent Drugs 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 12
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 3
- -1 hydroxy, hydroxy Chemical group 0.000 claims description 196
- 125000000217 alkyl group Chemical group 0.000 claims description 91
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 56
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 50
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 47
- 239000001257 hydrogen Substances 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 37
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 35
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 32
- 150000002431 hydrogen Chemical class 0.000 claims description 32
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 31
- 125000004122 cyclic group Chemical group 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 26
- 125000005842 heteroatom Chemical group 0.000 claims description 26
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 24
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 239000000651 prodrug Substances 0.000 claims description 24
- 229940002612 prodrug Drugs 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 23
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 22
- 229910052731 fluorine Inorganic materials 0.000 claims description 21
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims description 20
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims description 19
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 19
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 19
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 19
- 239000011737 fluorine Substances 0.000 claims description 19
- 229930192474 thiophene Natural products 0.000 claims description 19
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 125000003282 alkyl amino group Chemical group 0.000 claims description 15
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 13
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 claims description 13
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 125000004076 pyridyl group Chemical group 0.000 claims description 13
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims description 12
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 12
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 12
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 12
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 11
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 11
- 125000002883 imidazolyl group Chemical group 0.000 claims description 11
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 11
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 claims description 11
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 claims description 11
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 claims description 10
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims description 10
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 claims description 10
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 10
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 9
- VBXZSFNZVNDOPB-UHFFFAOYSA-N 1,4,5,6-tetrahydropyrimidine Chemical compound C1CNC=NC1 VBXZSFNZVNDOPB-UHFFFAOYSA-N 0.000 claims description 9
- OKGNMRKOGWTADH-UHFFFAOYSA-N 1,4-dihydropyrimidine Chemical compound C1C=CNC=N1 OKGNMRKOGWTADH-UHFFFAOYSA-N 0.000 claims description 9
- WUCWFMVYIKMAPG-UHFFFAOYSA-N 2,3-dihydropyrazine Chemical compound C1CN=CC=N1 WUCWFMVYIKMAPG-UHFFFAOYSA-N 0.000 claims description 9
- NZHIIDNOLFOHSG-UHFFFAOYSA-N 2,3-dihydropyridine Chemical compound C1CN=CC=C1 NZHIIDNOLFOHSG-UHFFFAOYSA-N 0.000 claims description 9
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 claims description 9
- MUGSKSNNEORSJG-UHFFFAOYSA-N 3174-74-1 Chemical compound C1CC=CCO1 MUGSKSNNEORSJG-UHFFFAOYSA-N 0.000 claims description 9
- BBZZGDLNBVRFFI-UHFFFAOYSA-N 4,5-dihydropyrimidine Chemical compound C1CN=CN=C1 BBZZGDLNBVRFFI-UHFFFAOYSA-N 0.000 claims description 9
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 9
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 9
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 9
- MUKXJDPQWWJDSX-UHFFFAOYSA-N 2,3-dihydropyrrole Chemical compound C1CC=C[N]1 MUKXJDPQWWJDSX-UHFFFAOYSA-N 0.000 claims description 8
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 claims description 8
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- OQJVXNHMUWQQEW-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazine Chemical compound C1CNC=CN1 OQJVXNHMUWQQEW-UHFFFAOYSA-N 0.000 claims description 7
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 7
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000002619 bicyclic group Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 5
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 claims description 4
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 150000003852 triazoles Chemical class 0.000 claims description 4
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims description 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 10
- 229920006395 saturated elastomer Polymers 0.000 description 41
- 238000006243 chemical reaction Methods 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- 125000002950 monocyclic group Chemical group 0.000 description 15
- 125000006413 ring segment Chemical group 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 230000000844 anti-bacterial effect Effects 0.000 description 13
- 238000001819 mass spectrum Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 11
- 125000003003 spiro group Chemical group 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 8
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 125000002837 carbocyclic group Chemical group 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241000192125 Firmicutes Species 0.000 description 7
- 125000005605 benzo group Chemical group 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 6
- 229960003907 linezolid Drugs 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- WGZYVHFXLPDNDL-UHFFFAOYSA-N 4-benzoyl-2-phenylpyrazole-3-carbonitrile Chemical compound C=1C=CC=CC=1C(=O)C(=C1C#N)C=NN1C1=CC=CC=C1 WGZYVHFXLPDNDL-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 125000005577 anthracene group Chemical group 0.000 description 5
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 5
- 125000001715 oxadiazolyl group Chemical group 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 4
- 0 C*(C[C@@](CN1c(cc2F)ccc2NCCO)OC1=O)C(C)=O Chemical compound C*(C[C@@](CN1c(cc2F)ccc2NCCO)OC1=O)C(C)=O 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 229960003085 meticillin Drugs 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 125000002098 pyridazinyl group Chemical group 0.000 description 4
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 3
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 3
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 3
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 3
- QQKJLBWCCMBWBE-UHFFFAOYSA-N 2-ethenylsulfanylethanethial Chemical compound C=CSCC=S QQKJLBWCCMBWBE-UHFFFAOYSA-N 0.000 description 3
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 3
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 3
- BGKABGGFJSTLIL-UHFFFAOYSA-N 3-(hydroxymethyl)-1,3-oxazolidin-2-one Chemical compound OCN1CCOC1=O BGKABGGFJSTLIL-UHFFFAOYSA-N 0.000 description 3
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 3
- MRUWJENAYHTDQG-UHFFFAOYSA-N 4H-pyran Chemical compound C1C=COC=C1 MRUWJENAYHTDQG-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- CVQUWLDCFXOXEN-UHFFFAOYSA-N Pyran-4-one Chemical compound O=C1C=COC=C1 CVQUWLDCFXOXEN-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 125000005956 isoquinolyl group Chemical group 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000005493 quinolyl group Chemical group 0.000 description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical group C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 2
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 2
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 2
- QVFHFKPGBODJJB-UHFFFAOYSA-N 1,3-oxathiane Chemical compound C1COCSC1 QVFHFKPGBODJJB-UHFFFAOYSA-N 0.000 description 2
- ARGCQEVBJHPOGB-UHFFFAOYSA-N 2,5-dihydrofuran Chemical compound C1OCC=C1 ARGCQEVBJHPOGB-UHFFFAOYSA-N 0.000 description 2
- WURYWHAKEJHAOV-UHFFFAOYSA-N 2,5-dihydrothiophene Chemical compound C1SCC=C1 WURYWHAKEJHAOV-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- MHNNAWXXUZQSNM-UHFFFAOYSA-N 2-methylbut-1-ene Chemical compound CCC(C)=C MHNNAWXXUZQSNM-UHFFFAOYSA-N 0.000 description 2
- NTYABNDBNKVWOO-UHFFFAOYSA-N 2h-1,3-thiazine Chemical compound C1SC=CC=N1 NTYABNDBNKVWOO-UHFFFAOYSA-N 0.000 description 2
- ZAISDHPZTZIFQF-UHFFFAOYSA-N 2h-1,4-thiazine Chemical compound C1SC=CN=C1 ZAISDHPZTZIFQF-UHFFFAOYSA-N 0.000 description 2
- LHAMNQGGGDUVFZ-UHFFFAOYSA-N 3,4-dihydrodiazete Chemical compound C1CN=N1 LHAMNQGGGDUVFZ-UHFFFAOYSA-N 0.000 description 2
- OJNYWHSZTYNGPE-UHFFFAOYSA-N 3-[(4-chlorophenyl)methylsulfanyl]-5-(methylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NC)SN=C1SCC1=CC=C(Cl)C=C1 OJNYWHSZTYNGPE-UHFFFAOYSA-N 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- ZOXMLSDKXHNVOQ-UHFFFAOYSA-N 4h-1,4-thiazine Chemical group N1C=CSC=C1 ZOXMLSDKXHNVOQ-UHFFFAOYSA-N 0.000 description 2
- YPXAASDZAZBHMG-UHFFFAOYSA-N 5,6-dihydro-4h-1,3-thiazine Chemical compound C1CSC=NC1 YPXAASDZAZBHMG-UHFFFAOYSA-N 0.000 description 2
- VNCVSCGVODHWLX-UHFFFAOYSA-N 6h-1,3-thiazine Chemical compound C1SC=NC=C1 VNCVSCGVODHWLX-UHFFFAOYSA-N 0.000 description 2
- QFPDHKBNCJAOKJ-UHFFFAOYSA-N 6h-oxazine Chemical compound C1ON=CC=C1 QFPDHKBNCJAOKJ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 2
- LYCITGUZCIFODE-UHFFFAOYSA-N CC1(C)OB(c(ccc(N(CC(CO)O2)C2=O)c2)c2F)OC1(C)C Chemical compound CC1(C)OB(c(ccc(N(CC(CO)O2)C2=O)c2)c2F)OC1(C)C LYCITGUZCIFODE-UHFFFAOYSA-N 0.000 description 2
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- QWHNJUXXYKPLQM-UHFFFAOYSA-N dimethyl cyclopentane Natural products CC1(C)CCCC1 QWHNJUXXYKPLQM-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910001389 inorganic alkali salt Inorganic materials 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 150000002696 manganese Chemical class 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- BDJAEZRIGNCQBZ-UHFFFAOYSA-N methylcyclobutane Chemical compound CC1CCC1 BDJAEZRIGNCQBZ-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 125000005561 phenanthryl group Chemical group 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RRKODOZNUZCUBN-CCAGOZQPSA-N (1z,3z)-cycloocta-1,3-diene Chemical group C1CC\C=C/C=C\C1 RRKODOZNUZCUBN-CCAGOZQPSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical class O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- 125000006079 1,1,2-trimethyl-2-propenyl group Chemical group 0.000 description 1
- 125000006059 1,1-dimethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006033 1,1-dimethyl-2-propenyl group Chemical group 0.000 description 1
- 125000006060 1,1-dimethyl-3-butenyl group Chemical group 0.000 description 1
- OFZYBEBWCZBCPM-UHFFFAOYSA-N 1,1-dimethylcyclobutane Chemical compound CC1(C)CCC1 OFZYBEBWCZBCPM-UHFFFAOYSA-N 0.000 description 1
- QEGNUYASOUJEHD-UHFFFAOYSA-N 1,1-dimethylcyclohexane Chemical group CC1(C)CCCCC1 QEGNUYASOUJEHD-UHFFFAOYSA-N 0.000 description 1
- PBIJFSCPEFQXBB-UHFFFAOYSA-N 1,1-dimethylcyclopropane Chemical compound CC1(C)CC1 PBIJFSCPEFQXBB-UHFFFAOYSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- CDMBDSJGCTWWJW-UHFFFAOYSA-N 1,2,3,6-tetrahydropyrrolo[3,4-c]pyrrole Chemical compound C1N=CC2=C1CNC2 CDMBDSJGCTWWJW-UHFFFAOYSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- 125000006034 1,2-dimethyl-1-propenyl group Chemical group 0.000 description 1
- 125000006035 1,2-dimethyl-2-propenyl group Chemical group 0.000 description 1
- 125000006063 1,2-dimethyl-3-butenyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical compound C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 1
- 125000006064 1,3-dimethyl-1-butenyl group Chemical group 0.000 description 1
- 125000006065 1,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006073 1-ethyl-1-butenyl group Chemical group 0.000 description 1
- 125000006080 1-ethyl-1-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006036 1-ethyl-1-propenyl group Chemical group 0.000 description 1
- 125000006074 1-ethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006081 1-ethyl-2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006082 1-ethyl-2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006037 1-ethyl-2-propenyl group Chemical group 0.000 description 1
- 125000006075 1-ethyl-3-butenyl group Chemical group 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006025 1-methyl-1-butenyl group Chemical group 0.000 description 1
- 125000006019 1-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006028 1-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006048 1-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006030 1-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000006052 1-methyl-3-pentenyl group Chemical group 0.000 description 1
- 125000006055 1-methyl-4-pentenyl group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- POXWDTQUDZUOGP-UHFFFAOYSA-N 1h-1,4-diazepine Chemical compound N1C=CC=NC=C1 POXWDTQUDZUOGP-UHFFFAOYSA-N 0.000 description 1
- 125000006067 2,2-dimethyl-3-butenyl group Chemical group 0.000 description 1
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 1
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 1
- 125000006068 2,3-dimethyl-1-butenyl group Chemical group 0.000 description 1
- 125000006069 2,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006070 2,3-dimethyl-3-butenyl group Chemical group 0.000 description 1
- NNTHYKIREYJASD-UHFFFAOYSA-N 2-(2-fluoro-4-nitrophenyl)-5-(2-methyltetrazol-5-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole Chemical compound CN1N=NC(N2CC3=NN(C=C3C2)C=2C(=CC(=CC=2)[N+]([O-])=O)F)=N1 NNTHYKIREYJASD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006076 2-ethyl-1-butenyl group Chemical group 0.000 description 1
- 125000006077 2-ethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006078 2-ethyl-3-butenyl group Chemical group 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006026 2-methyl-1-butenyl group Chemical group 0.000 description 1
- 125000006045 2-methyl-1-pentenyl group Chemical group 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006049 2-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006031 2-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000006053 2-methyl-3-pentenyl group Chemical group 0.000 description 1
- 125000006056 2-methyl-4-pentenyl group Chemical group 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- WWUVJRULCWHUSA-UHFFFAOYSA-N 2MP Natural products CCCC(C)=C WWUVJRULCWHUSA-UHFFFAOYSA-N 0.000 description 1
- MSRJJSCOWHWGGX-UHFFFAOYSA-N 2h-1,3-diazepine Chemical compound C1N=CC=CC=N1 MSRJJSCOWHWGGX-UHFFFAOYSA-N 0.000 description 1
- KGWNRZLPXLBMPS-UHFFFAOYSA-N 2h-1,3-oxazine Chemical compound C1OC=CC=N1 KGWNRZLPXLBMPS-UHFFFAOYSA-N 0.000 description 1
- YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 description 1
- 125000006071 3,3-dimethyl-1-butenyl group Chemical group 0.000 description 1
- 125000006072 3,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
- DNUJVGBNIXGTHC-UHFFFAOYSA-N 3,6-dihydro-2h-oxazine Chemical compound C1NOCC=C1 DNUJVGBNIXGTHC-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000006027 3-methyl-1-butenyl group Chemical group 0.000 description 1
- 125000006046 3-methyl-1-pentenyl group Chemical group 0.000 description 1
- 125000006050 3-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000006054 3-methyl-3-pentenyl group Chemical group 0.000 description 1
- 125000006057 3-methyl-4-pentenyl group Chemical group 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- XYVMOLOUBJBNBF-UHFFFAOYSA-N 3h-1,3-oxazol-2-one Chemical compound OC1=NC=CO1 XYVMOLOUBJBNBF-UHFFFAOYSA-N 0.000 description 1
- XBZLGTFOMXCHPP-UHFFFAOYSA-N 4-[[4-(2-methoxyphenyl)-1,3-thiazol-2-yl]amino]benzoic acid Chemical compound COC1=CC=CC=C1C1=CSC(NC=2C=CC(=CC=2)C(O)=O)=N1 XBZLGTFOMXCHPP-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000006047 4-methyl-1-pentenyl group Chemical group 0.000 description 1
- 125000006051 4-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006058 4-methyl-4-pentenyl group Chemical group 0.000 description 1
- IQOZTIKBIHWYQQ-UHFFFAOYSA-N 4h-1,3-oxazine Chemical compound C1C=COC=N1 IQOZTIKBIHWYQQ-UHFFFAOYSA-N 0.000 description 1
- ORLOHKLQCQERNP-UHFFFAOYSA-N 4h-1,3-thiazine Chemical compound C1C=CSC=N1 ORLOHKLQCQERNP-UHFFFAOYSA-N 0.000 description 1
- UOSQFVCDJBZRKS-UHFFFAOYSA-N 4h-1,4-oxazine Chemical compound N1C=COC=C1 UOSQFVCDJBZRKS-UHFFFAOYSA-N 0.000 description 1
- BMRPOOWUTVUBRI-UHFFFAOYSA-N 4h-oxazine Chemical compound C1C=CON=C1 BMRPOOWUTVUBRI-UHFFFAOYSA-N 0.000 description 1
- KJCXRORGYAHAAH-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1h-isoindole Chemical compound BrC1=CC=C2CNCC2=C1 KJCXRORGYAHAAH-UHFFFAOYSA-N 0.000 description 1
- FCWAEMGWOGFTJN-UHFFFAOYSA-N 5-bromo-2-(2-methyltetrazol-5-yl)-1,3-dihydroisoindole Chemical compound CN1N=NC(N2CC3=CC(Br)=CC=C3C2)=N1 FCWAEMGWOGFTJN-UHFFFAOYSA-N 0.000 description 1
- ZMNDGVWCBBMCNV-UHFFFAOYSA-N 5-bromo-2-(2h-tetrazol-5-yl)-1,3-dihydroisoindole Chemical compound C1C2=CC(Br)=CC=C2CN1C=1N=NNN=1 ZMNDGVWCBBMCNV-UHFFFAOYSA-N 0.000 description 1
- IZSHZLKNFQAAKX-UHFFFAOYSA-N 5-cyclopenta-2,4-dien-1-ylcyclopenta-1,3-diene Chemical group C1=CC=CC1C1C=CC=C1 IZSHZLKNFQAAKX-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- GMLMFZXBPRIXPK-UHFFFAOYSA-N 6h-1,3-oxazine Chemical compound C1OC=NC=C1 GMLMFZXBPRIXPK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- FHWYPZCCHIGUBV-UHFFFAOYSA-N Brc1cc(CN(C2)c3ncc[nH]3)c2cc1 Chemical compound Brc1cc(CN(C2)c3ncc[nH]3)c2cc1 FHWYPZCCHIGUBV-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- WTFBYYGMNGXMTC-UHFFFAOYSA-N C(C1OC(COC2)C2OC1)[O]1CC(C2)C2C1 Chemical compound C(C1OC(COC2)C2OC1)[O]1CC(C2)C2C1 WTFBYYGMNGXMTC-UHFFFAOYSA-N 0.000 description 1
- CBKDCOKSXCTDAA-UHFFFAOYSA-N C(CC1)Cc2c1[s]cc2 Chemical compound C(CC1)Cc2c1[s]cc2 CBKDCOKSXCTDAA-UHFFFAOYSA-N 0.000 description 1
- SHSKIPABCDWHCZ-UHFFFAOYSA-N C(COC1)c2c1cc[nH]2 Chemical compound C(COC1)c2c1cc[nH]2 SHSKIPABCDWHCZ-UHFFFAOYSA-N 0.000 description 1
- AKSRFDKEKIPHHI-UHFFFAOYSA-N C1CC2OCCOC2C1 Chemical compound C1CC2OCCOC2C1 AKSRFDKEKIPHHI-UHFFFAOYSA-N 0.000 description 1
- YBBLSBDJIKMXNQ-UHFFFAOYSA-N C1Nc2ccccc2SC1 Chemical compound C1Nc2ccccc2SC1 YBBLSBDJIKMXNQ-UHFFFAOYSA-N 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N C1Oc(cccc2)c2OC1 Chemical compound C1Oc(cccc2)c2OC1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- HUROOLUXCCGNII-DVZNUREQSA-N CN(C)/C=C(/COCC1)\C1=N Chemical compound CN(C)/C=C(/COCC1)\C1=N HUROOLUXCCGNII-DVZNUREQSA-N 0.000 description 1
- DOKBPGCLWGBGMY-UHFFFAOYSA-N C[n]1nccc1N(C1)Cc2c1ccc(Br)c2 Chemical compound C[n]1nccc1N(C1)Cc2c1ccc(Br)c2 DOKBPGCLWGBGMY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical compound C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 150000001537 azepanes Chemical class 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- LHLKGCMCFFJNCS-UHFFFAOYSA-N benzyl n-(3-fluorophenyl)carbamate Chemical compound FC1=CC=CC(NC(=O)OCC=2C=CC=CC=2)=C1 LHLKGCMCFFJNCS-UHFFFAOYSA-N 0.000 description 1
- UPTMRBYILBFUPA-UHFFFAOYSA-N benzyl n-(4-bromo-3-fluorophenyl)carbamate Chemical compound C1=C(Br)C(F)=CC(NC(=O)OCC=2C=CC=CC=2)=C1 UPTMRBYILBFUPA-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- SGZWYNUJLMTSMJ-UHFFFAOYSA-N benzyl n-phenylcarbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1=CC=CC=C1 SGZWYNUJLMTSMJ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- YZLCEXRVQZNGEK-UHFFFAOYSA-N bicyclo[2.2.0]hexane Chemical compound C1CC2CCC21 YZLCEXRVQZNGEK-UHFFFAOYSA-N 0.000 description 1
- JAPMJSVZDUYFKL-UHFFFAOYSA-N bicyclo[3.1.0]hexane Chemical group C1CCC2CC21 JAPMJSVZDUYFKL-UHFFFAOYSA-N 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- SGCLBIRCSTXTIU-UHFFFAOYSA-N boric acid;2,3-dimethylbutane-2,3-diol Chemical compound OB(O)O.CC(C)(O)C(C)(C)O.CC(C)(O)C(C)(C)O SGCLBIRCSTXTIU-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000007697 cis-trans-isomerization reaction Methods 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- GKWVPUHAFAYKSZ-UHFFFAOYSA-N cyclohexa-1,5-dien-1-amine Chemical compound NC1=CCCC=C1 GKWVPUHAFAYKSZ-UHFFFAOYSA-N 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- OOXWYYGXTJLWHA-UHFFFAOYSA-N cyclopropene Chemical compound C1C=C1 OOXWYYGXTJLWHA-UHFFFAOYSA-N 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- YRTMEEURRDTMST-UHFFFAOYSA-N diazetidine Chemical compound C1CNN1 YRTMEEURRDTMST-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- CTGHONDBXRRMRC-UHFFFAOYSA-N dithiete Chemical compound C1=CSS1 CTGHONDBXRRMRC-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- RYPKRALMXUUNKS-UHFFFAOYSA-N hex-2-ene Chemical compound CCCC=CC RYPKRALMXUUNKS-UHFFFAOYSA-N 0.000 description 1
- 125000004871 hexylcarbonyl group Chemical group C(CCCCC)C(=O)* 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000006328 iso-butylcarbonyl group Chemical group [H]C([H])([H])C([H])(C(*)=O)C([H])([H])[H] 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910001463 metal phosphate Inorganic materials 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical group CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 1
- VNXBKJFUJUWOCW-UHFFFAOYSA-N methylcyclopropane Chemical compound CC1CC1 VNXBKJFUJUWOCW-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229910002055 micronized silica Inorganic materials 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005933 neopentyloxycarbonyl group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000004675 pentylcarbonyl group Chemical group C(CCCC)C(=O)* 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000004673 propylcarbonyl group Chemical group 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005930 sec-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007944 soluble tablet Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Definitions
- the present invention relates to the field of medical technology, and in particular to a cyclohexanone antibiotic, a pharmaceutically acceptable salt thereof, an isomer thereof or a prodrug thereof, a preparation method of the compound, a pharmaceutical composition containing the same, and Pharmaceutical preparations, and the use of these compounds in the preparation of a medicament for the treatment and/or prevention of infectious diseases and for the treatment and/or prevention of infectious diseases.
- the oxazolidinone antibacterial agents are a new class of chemically synthetic antibacterial drugs developed after sulfonamides and fluoroquinolones, and have the effect of inhibiting multi-drug resistant Gram-positive bacteria.
- Linezolid is the first commercially available *azole
- Linezolid is mainly used for the treatment of infectious diseases caused by resistant Gram-positive bacteria, and also for the treatment of surgical infectious diseases.
- the present invention provides a class of anti-infective compounds having better antibacterial activity, and the specific technical scheme is as follows:
- R 1 is selected from (1) OR 7 , (2) - NR 7 R 7 ', (3) COR 7 , (4) - COOR 7 , (5) OCO 7 , (6) -CON 7 7 ', (7 )-N 7 CO 7 ', (8) -OCON 7 , (9) -N 7 COO 7 ' , (10) -N 7 CON 7 7 , (11) CSR 7 , (12) CSO 7 , (13) OCSR 7 , (14) — CSNR 7 R 7 ', (15) — NR 7 CSR 7 ', (16) -OCSN 7 , (17)-N 7 CSO 7 ⁇ (18) -N 7 CSN 7 7 , ( 19) -N 7 C(N 7 )N 7 7 , (20) -S(0) P 7 , (21)-S0 2 N 7 7 ', or (22)R 7 ,
- p 0, 1 or 2
- R 7 and R 7 ' are selected from the group consisting of: (1) H, (2) d alkyl, (3) C 2 - 6 alkenyl, (4) C 2-6 alkynyl, (5) 3-14-membered ring An alkyl group or a 6-14 membered aryl group, (6) a 3-14 membered heterocyclic group containing one or more selected from N, S, O and Z or S0 2 heteroatoms, (7)-COC 1- 6 alkyl, (8)-COC 2 - 6 alkenyl, or (9)-COC 2 - 6 alkynyl;
- R 2 , R 3 are independently selected from the group consisting of hydrogen, halogen, C alkyl, d. 6 alkylamino, bis(CL 6 alkyl)amino or d. 6 alkoxy; a parallel fused bicyclic system composed of A ring and B ring,
- the A ring is selected from a 3-8 membered cyclic group which is unsubstituted or substituted with 1-3 R 5 , wherein said R 5 is independently selected from the group consisting of hydrogen, halogen, CL 6 alkyl, halogenated d. 6 alkyl, hydroxy, hydroxy d- 6 alkyl, amino, d- 6 alkylamino, bis(d. 6 alkyl)amino or d alkylcarbamoyl;
- the B ring is selected from a benzene ring or a 5-membered heteroaryl group which is unsubstituted or substituted with 1-3 R 4 , wherein said R 4 is independently selected from the group consisting of hydrogen, halogen, CL 6 alkyl, halogenated d alkyl , hydroxy, hydroxy d. 6 alkyl, amino, d alkylamino, bis(C ⁇ alkylamino or alkylcarbamoyl;
- R 6 is selected from unsubstituted or substituted by 1-3 substituents 18 of the following groups:
- R S is selected from the group consisting of a carboxylic acid, a hydroxy group, an amino group, a cyano group, a nitro group, a CL 6 alkyl group, a carboxyl group d. 6 alkyl group, a hydroxy CL 6 alkyl group, an aminoalkyl group, a halogenated alkyl group, and a d. 6 alkoxy group.
- R 1 is selected from the group consisting of acetylamino, hydroxy, 1,2,3-triazolyl or isoxazolyloxy;
- R 3 is independently selected from hydrogen or halogen
- the A ring is selected from a 5-6 membered cycloalkyl group or a 5-6 membered heterocyclic group which is unsubstituted or substituted with 1 to 2 R 5 groups, wherein said R 5 is independently selected from the group consisting of hydrogen, halogen, d 4 alkyl Base, halogenated d 4 alkyl, hydroxy, hydroxy d. 4 alkyl, amino, C 1 alkylamino, bis(C 14 alkyl)amino or C 14 alkylcarbamoyl;
- the B ring is selected from a benzene ring or a 5-membered heteroaryl group which is unsubstituted or substituted with 1-2 R 4 groups, wherein R 4 is independently selected from the group consisting of hydrogen, halogen, CM alkyl, halo CM alkyl, Hydroxy, hydroxy CM alkyl, amino, CM alkylamino, bis(d alkyl)amino or CM alkylcarbamoyl;
- R 6 is selected from 5-6 membered heteroaryl groups containing 1, 2, 3 or 4 N atoms which are unsubstituted or substituted by 1 to 2 R 8 , wherein said 18 is selected from unsubstituted or A CM alkyl group substituted with a halogen.
- R 1 is an acetylamino group or a hydroxyl group
- R 3 is independently selected from hydrogen or fluorine
- Ring A is selected from the group consisting of unsubstituted or substituted by 1 - 2 R 5 : cyclopentane, cyclohexane, tetrahydropyrrole, 2,3-dihydropyrrole, 2,5-dihydropyrrole , pyrrole, imidazole, 4,5-dihydroimidazole, pyrazole, 4,5-dihydropyrazole, 1,2,3-triazole, tetrahydrothiophene, thiophene, 2,3-dihydrothiophene, thiazole , 4,5-dihydrothiazole, isothiazole, tetrahydrofuran, 2,3-dihydrofuran, furan, 4,5-dihydro 3 ⁇ 4azole, oxazole, 4,5-dihydroisoxazole, isoxazole , phenyl ring, 1,4,5,6-tetrahydropyrim
- the B ring is selected from a benzene ring or a 5-membered heteroaryl group which is unsubstituted or substituted by 1-2 R 4 , wherein said R 4 is independently selected from the group consisting of hydrogen, fluorine, methyl, fluoromethyl, trifluoro Methyl, hydroxy, hydroxymethyl, amino, methylamino, ethylamino, methylcarbamoyl or ethylcarbamoyl;
- R 6 is selected from the group consisting of the following groups which are unsubstituted or substituted by 1-2 R s : pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4- Triazolyl, 1,2,3,4-tetrazolyl, pyridyl or pyrazinyl, wherein the 18 is selected from the group consisting of methyl, ethyl, propyl or trifluoromethyl. More preferably:
- R 1 is an acetylamino group or a hydroxyl group
- R 2 and R 3 are independently selected from hydrogen or fluorine
- Ring A is selected from the group consisting of unsubstituted or substituted by 1-2 R 5 : cyclopentane, cyclohexane, tetrahydropyrrole, 2,3-dihydropyrrole, 2,5-dihydropyrrole , pyrrole, imidazole, 4,5-dihydroimidazole, pyrazole, 4,5-dihydropyrazole, 1,2,3-triazole, tetrahydrothiophene, thiophene, 2,3-dihydrothiophene, thiazole , 4,5-dihydrothiazole, isothiazole, tetrahydrofuran, 2,3-dihydrofuran, furan, 4,5-dihydro 3 ⁇ 4azole, oxazole, 4,5-dihydroisoxazole, isoxazole , phenyl ring, 1,4,5,6-tetrahydropyrimidine,
- Ring B is selected from benzene rings which are unsubstituted or substituted by 1-2 R 4 , thiazole, imidazole, thiophene, furan, pyrazole, pyrrole, 1,2,3-triazole, 1,2,4 -Triazole, 1,2,3,4-tetrazole, xazole wherein R 4 is independently selected from the group consisting of hydrogen, fluorine, methyl, fluoromethyl, trifluoromethyl, hydroxy, hydroxymethyl, amino , methylamino, ethylamino, methylcarbamoyl or ethylcarbamoyl;
- R 6 is selected from unsubstituted or substituted with 1 to 2 18 of the following groups: pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazole, 1,2,4- Triazolyl, 1,2,3,4-tetrazolyl, pyridyl or pyrazinyl, wherein the 18 is selected from the group consisting of methyl, ethyl, propyl or trifluoromethyl. Further preferably - wherein R 1 is an acetylamino group or a hydroxyl group;
- R 3 is independently selected from hydrogen or fluorine
- Ring A is selected from the group consisting of unsubstituted or substituted by 1-2 R 5 : cyclopentane, cyclohexane, tetrahydropyrrole, 2,3-dihydropyrrole, 2,5-dihydropyrrole , pyrrole, imidazole, 4,5-dihydroimidazole, pyrazole, 4,5-dihydropyrazole, 1,2,3-triazole, tetrahydrothiophene, thiophene, 2,3-dihydrothiophene, thiazole , 4,5-dihydrothiazole, tetrahydrofuran, 2,3-dihydrofuran, furan, oxazole, benzene ring, 1,4,5,6-tetrahydropyrimidine, 1,6-dihydropyrimidine, 4,5 -dihydropyrimidine, pyrimidine, 3,6-dihydro-2H-pyr
- Ring B is selected from benzene rings which are unsubstituted or substituted by 1-2 R 4 , thiazole, imidazole, thiophene, furan, pyrazole, pyrrole, 1,2,3-triazole, 1,2,4 a triazole, an azole, wherein said R 4 is selected from the group consisting of hydrogen, fluorine, methyl or fluoromethyl;
- R 6 is selected from 1,2,3-triazolyl, 1,2,4-triazolyl or 1,2,3,4-tetrazole which is unsubstituted or substituted by 1-2. a group, wherein the 5 ⁇ is selected from a methyl group or an ethyl group.
- 1 is selected from (1) -OR 7 , (2) -N 7 , (3) -COR 7 , (4) -COO 7 , (5) -OCO 7 , (6) CONR 7 7 ', (7) NR 7 COR 7 ', (8) OCONRV, (9) NR 7 COO 7 ' , (10) -N 7 CONR 7 7 , (11) -CS 7 , (12) -CSO 7 , (13) -OCS 7 , (14) — CSNR 7 R 7 ', (15) - N 7 CS R , (16) OCSNRV , (17) NR 7 CSOR 7 ', (18) NR 7 CSNR 7 , (19) -N 7 C( N 7 )NR 7 R 7 , (20) -S(0) P 7 , (21)-SO ⁇ 7 R 7 ', or (22)R 7 ,
- p 0, 1 or 2
- R 7 and R 7 ' are selected from the group consisting of: (1) H, (2) d alkyl, (3) C 2 - 6 alkenyl, (4) C 2-6 alkynyl, (5) 3-14-membered ring An alkyl group or a 6-14 membered aryl group, (6) a 3-14 membered heterocyclic group containing one or more selected from N, S, O and Z or S0 2 heteroatoms, (7)-COC 1- 6 alkyl, (8)-COC 2 - 6 alkenyl, or (9) - COC 2 - 6 alkynyl;
- R 2 > R 3 are independently selected from the group consisting of hydrogen, halogen, .6 alkyl, .6 alkylamino, dialkyl)amino or alkoxy; a parallel fused bicyclic system composed of A ring and B ring,
- the A ring is selected from a 3-8 membered cyclic group which is unsubstituted or substituted with 1-3 R 5 , wherein said R 5 is independently selected from the group consisting of hydrogen, halogen, CL 6 alkyl, halogenated d. 6 alkyl, hydroxy, hydroxy d alkyl, amino, d alkylamino, dialkyl) amino or alkylcarbamoyl;
- the B ring is selected from a benzene ring or a 5-membered heteroaryl group which is unsubstituted or substituted with 1-3 R 4 , wherein said R 4 is independently selected from the group consisting of hydrogen, halogen, alkyl, halo d- 6 alkyl, Hydroxy, hydroxy d. 6 alkyl, amino, d- 6 alkylamino, bis(d alkyl)amino or alkylcarbamoyl;
- R 6 is selected from unsubstituted or substituted by 1-3 substituents 18 following groups -
- R s is selected from the group consisting of a carboxy group, a hydroxy group, an amino group, a cyano group, a nitro group, an alkyl group, a carboxyl group d. 6 alkyl group, a hydroxy CL 6 alkyl group, an amino d- 6 alkyl group, a halogenated d 6 alkyl group, d.
- R 1 is selected from the group consisting of acetylamino, hydroxy, 1,2,3-triazolyl or isoxazolyloxy;
- R 2 and R 3 are independently selected from hydrogen or halogen
- the A ring is selected from a 5-6 membered cycloalkyl group or a 5-6 membered heterocyclic group which is unsubstituted or substituted with 1-2 R 5 groups, wherein said R 5 is independently selected from the group consisting of hydrogen, halogen, d- 4 alkane Base, halo CM alkyl, hydroxy, hydroxy CM alkyl, amino, CL4 alkylamino, bis( -4 alkyl:)amino or d- 4 alkylcarbamoyl;
- the B ring is selected from a benzene ring or a 5-membered heteroaryl group which is unsubstituted or substituted with 1-2 R 4 groups, wherein said R 4 is independently selected from the group consisting of hydrogen, halogen, CM alkyl, halo CM alkyl, Hydroxy, hydroxy CM alkyl, amino, CM alkylamino, bis(d alkyl)amino or CM alkylcarbamoyl;
- R 6 is selected from 5-6 membered impurities containing 1, 2, 3 or 4 N atoms which are unsubstituted or substituted by 1-2
- R 8 An aryl group, wherein the 18 is selected from CM alkyl groups which are unsubstituted or substituted by halogen.
- - wherein
- R 1 is an acetylamino group or a hydroxyl group
- R 2 and R 3 are independently selected from hydrogen or fluorine
- Ring A is selected from the group consisting of unsubstituted or substituted by 1-2 R 5 : cyclopentane, cyclohexane, tetrahydropyrrole, 2,3-dihydropyrrole, 2,5-dihydropyrrole , pyrrole, imidazole, 4,5-dihydroimidazole, pyrazole, 4,5-dihydropyrazole, 1,2,3-triazole, tetrahydrothiophene, thiophene, 2,3-dihydrothiophene, thiazole , 4,5-dihydrothiazole, isothiazole, tetrahydrofuran, 2,3-dihydrofuran, furan, 4,5-dihydrooxazole, oxazole, 4,5-dihydroisoxazole, iso-oxazole, Benzene ring, 1,4,5,6-tetrahydropyrimidine,
- the B ring is selected from a benzene ring or a 5-membered heteroaryl group which is unsubstituted or substituted by 1-2 R 4 , wherein said R 4 is independently selected from the group consisting of hydrogen, fluorine, methyl, fluoromethyl, trifluoro Methyl, hydroxy, hydroxymethyl, amino, methylamino, ethylamino, methylcarbamoyl or ethylcarbamoyl;
- R 6 is selected from the following groups which are unsubstituted or substituted by 1-2 R S : pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4- Triazolyl, 1,2,3,4-tetrazolyl, pyridyl or pyrazinyl, wherein the 18 is selected from the group consisting of methyl, ethyl, propyl or trifluoromethyl. Further preferably - wherein
- R 1 is an acetylamino group or a hydroxyl group
- R 3 is independently selected from hydrogen or fluorine
- Ring A is selected from the group consisting of unsubstituted or substituted by 1-2 R 5 : cyclopentane, cyclohexane, tetrahydropyrrole, 2,3-dihydropyrrole, 2,5-dihydropyrrole , pyrrole, imidazole, 4,5-dihydroimidazole, pyrazole, 4,5-dihydropyrazole, 1,2,3-triazole, tetrahydrothiophene, thiophene, 2,3-dihydrothiophene, thiazole , 4,5-dihydrothiazole, isothiazole, tetrahydrofuran, 2,3-dihydrofuran, furan, 4,5-dihydro 3 ⁇ 4azole, oxazole, 4,5-dihydroisoxazole, isoxazole , phenyl ring, 1,4,5,6-tetrahydropyrimidine,
- Ring B is selected from benzene rings which are unsubstituted or substituted by 1-2 R 4 , thiazole, imidazole, thiophene, furan, pyrazole, pyrrole, 1,2,3-triazole, 1,2,4 a triazole, 1,2,3,4-tetrazole, oxazole, wherein said R 4 is independently selected from the group consisting of hydrogen, fluoro, methyl, fluoromethyl, trifluoromethyl, hydroxy, hydroxymethyl, Amino group, methylamino group, ethylamino group, methylcarbamoyl group or ethylcarbamoyl group;
- R 6 is selected from unsubstituted or substituted with 1 to 2 18 of the following groups: pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazole, 1,2,4- Triazolyl, 1,2,3,4-tetrazolyl, pyridyl or pyrazinyl, wherein said R s is selected from methyl, ethyl, propyl or trifluoromethyl. More preferably:
- R 1 is an acetylamino group or a hydroxyl group
- R 2 and R 3 are independently selected from hydrogen or fluorine
- Ring A is selected from the group consisting of unsubstituted or substituted by 1-2 R 5 : cyclopentane, cyclohexane, tetrahydropyrrole, 2,3-dihydropyrrole, 2,5-dihydropyrrole , pyrrole, imidazole, 4,5-dihydroimidazole, pyrazole, 4,5-dihydropyrazole, 1,2,3-triazole, tetrahydrothiophene, thiophene, 2,3-dihydrothiophene, thiazole , 4,5-dihydrothiazole, tetrahydrofuran, 2,3-dihydrofuran, furan, 3 ⁇ 4 azole, benzene ring, 1,4,5,6-tetrahydropyrimidine, 1,6-dihydropyrimidine, 4,5 -dihydropyrimidine, pyrimidine, 3,6-dihydro-2H-
- Ring B is selected from benzene rings which are unsubstituted or substituted by 1-2 R 4 , thiazole, imidazole, thiophene, furan, pyrazole, pyrrole, 1,2,3-triazole, 1,2,4 -Triazole, «azole, wherein said R 4 is selected from the group consisting of hydrogen, fluorine, methyl or fluoromethyl;
- R 6 is selected from unsubstituted or 1-2! ⁇ Substituted 1,2,3-triazolyl, 1,2,4-triazolyl or 1,2,3,4-tetrazolyl, wherein said R s is selected from methyl or ethyl.
- halogen in the present invention means a fluorine atom, a chlorine atom, a bromine atom, an iodine atom or the like.
- a fluorine atom and a chlorine atom are preferred.
- halo as used in the present invention means that an atom which may be substituted by any one of the groups is substituted by a halogen, and may be fully halogenated, that is, a position at which all of the halogen atom-substituted groups can be substituted.
- Cw alkyl group as used in the present invention means an alkane having 1 to 6 carbon atoms and a straight or branched alkyl group derived by removing one hydrogen atom, and specific examples include, but are not limited to, methyl group, ethyl group, and n-propyl group.
- Base isopropyl, n-butyl, 2-methylpropyl, 1-methylpropyl, 1,1-dimethylethyl, n-pentyl, 3-methylbutyl, 2-methylbutyl Base, 1-methylbutyl, 1-ethylpropyl, n-hexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3 - dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3 - dimethylbutyl, 2-ethylbutyl, 1-methyl-2-methylpropyl, and the like.
- the "C l alkyl group" as used in the present invention means a specific example containing from 1 to 4 carbon atoms in the above examples.
- C 2 -6 alkenyl group as used in the present invention means a linear or branched or cyclic alkenyl group having 2 to 6 carbon atoms and containing a double bond, and specific examples include, but are not limited to, vinyl, 1 -propenyl, 2-propenyl, 3-propenyl, 1-methylvinyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2 -Methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentyl Alkenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl 2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butene
- C 2 -6 alkynyl group as used in the present invention means a linear or branched alkynyl group having 2 to 6 carbon atoms and having a fluorene bond.
- Examples of the body include, but are not limited to: ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl,
- alkoxy group as used in the present invention means a group in which "d. 6 alkyl group” is bonded to other structures through an oxygen atom, and specific examples include, but are not limited to, methoxy group, ethoxy group, propoxy group, and ⁇ group. Ethyloxy, butoxy, ⁇ methylpropoxy,
- C 14 alkoxy group as used in the present invention means a specific example containing from 1 to 4 carbon atoms in the above examples.
- C ⁇ alkylcarbonyl group as used in the present invention means a group derived from the attachment of a d- 6 alkyl group to another moiety through a carbonyl group -C(O)-, that is, an alkyl group -C(0)-, said "" d.
- CM alkylcarbonyl group as used in the present invention means a specific example containing 1-4 carbon atoms in the above examples.
- Cw of alkylcarbonyloxy refers to d. 6 by a carboxy group -C (0) 0- portion connected to the other group derived, i.e., (d. 6 alkyl :) c ( o -, the "d alkyl" as described above, specific examples include, but are not limited to: methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, tert-butyl An oxycarbonyl group, a sec-butoxycarbonyl group, a pentyloxycarbonyl group, a neopentyloxycarbonyl group, a hexyloxycarbonyl group or the like.
- the "3-14 membered cycloalkyl group” as used in the present invention means that the alkane moiety of 3 to 14 carbon atoms is removed by a hydrogen atom-derived cyclic alkyl group, including a 3-8 membered monocyclic cycloalkyl group, 6-14. And a cycloalkyl group, a 7-12 membered bridged ring group and a 7-12 membered spiro ring group. Preferably 3 ⁇ 4. 8 cycloalkyl, C 3. 6 cycloalkyl, and 05 _ 6 cycloalkyl.
- "C 3 _ s cycloalkyl” according to the present invention, "C 3-6 cycloalkyl", “C 5. 6 cycloalkyl", "5-6 membered cycloalkyl” are the following examples Contains 3-8, 3-6, 5-6 A specific example of a carbon atom.
- a 3-8 membered monocyclic cycloalkyl group includes a 3-8 membered saturated monocyclic cycloalkyl group and a 3-8 membered partially saturated monocyclic cycloalkyl group.
- a 3-8-membered saturated monocyclic cycloalkyl group means that the monocyclic ring is an all-saturated carbocyclic ring, and specific examples include, but are not limited to, cyclopropyl group, cyclobutylalkyl group, cyclopentyl group, cyclohexane group, ring.
- a 3-8 membered partially saturated monocyclic cycloalkyl group means that the monocyclic ring is a partially saturated carbocyclic ring, and specific examples include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, 1 , 4-cyclohexadienyl, cycloheptenyl, 1,4-cycloheptadienyl, cyclooctenyl, 1,5-cyclooctadienyl, etc.;
- 6- 14-membered cyclocycloalkyl which refers to a 6-14 membered cyclic group formed by two or more cyclic structures sharing two adjacent carbon atoms, including 6-14 yuan saturated Cyclocycloalkyl and 6-14 membered partially saturated cyclocycloalkyl.
- a 6-12 membered cyclocycloalkyl group, 6-10 membered cyclocycloalkyl group is preferred.
- the 6-14-membered saturated cyclocycloalkyl group means that the ring-and-ring group is a fully saturated carbocyclic ring, and specific examples include, but are not limited to: bicyclo[3.1.0]hexane group, bicyclo[4.1.0] g.
- the 6-14 membered partially saturated cyclocycloalkyl group means that at least one ring in the parallel ring is a partially saturated carbocyclic ring, and specific examples include, but are not limited to: bicyclo[3.1.0]hex-2-enyl, bicyclo [ 4 ⁇ 0]hept-3-enyl, bicyclo[3.2.0]hept-3-enyl, bicyclo[4.2.0]oct-3-enyl, 1,2,3,3-tetrahydrocyclopentan Dienyl, 2,3,3,4,7,7 ⁇ -hexahydro-1H-indenyl, l,2,3,4,4a,5,6,8a-hydronaphthyl, 1,2,4 ⁇ , 5,6,8 ⁇ -hexahydronaphthyl, 1,2,3,4,5,6,7,8,9,10-decahydrophenanthyl;
- the 7- to 12-membered bridged ring group means that any two rings share a structure of 7-12 carbon atoms formed by two atoms not directly connected, and the "7-12-membered bridge ring" includes a 7-12-membered saturated bridged ring group. , 7-12 yuan partially saturated bridged ring base. 7-12 yuan saturated bridged ring group, preferably 6-10 yuan saturated bridged ring group, specific examples include, but are not limited to: bicyclo [2 ⁇ 1] hexane group, bicyclo [2.2.1] heptyl group, double ring [3.2.
- the 7-12-membered partially saturated bridged ring group means that at least one ring of the bridged ring is a cyclic group containing a double bond, preferably a 6-10 membered partially saturated bridged ring group, and specific examples include, but are not limited to: [2.2.1] hept-5-alkenyl, bicyclo[3.2.1]oct-6-alkenyl, bicyclo (4.3.0) fluoren-5-enyl, dicyclopentadienyl, etc.;
- the 7-12 member spiro group refers to a 7-12 membered ring structure formed by a class of at least two rings sharing one atom, including a 7-12 membered saturated spiro group and a 7-12 membered partially saturated spiro group. 7-12 yuan saturated
- Ring structure A group formed by substituting any substitutable hydrogen atom or the like.
- the 7-12-membered partially saturated spirocyclic group means that at least one ring of the spirocyclic group is a cyclic group containing a double bond, and specific examples include, but are not limited to:
- the cyclic group structure replaces a group formed by any substitutable hydrogen atom.
- a 7-10 membered spiro group is preferred, including "7-10 membered saturated spiro group" and "7-10 membered partially saturated spiro group”.
- C 3 .s cycloalkoxy group as used in the present invention means a group in which the term “C 3 s s cycloalkyl group” is bonded to other structures through an oxygen atom, and specific examples include, but are not limited to: cyclopropoxy group , cyclobutoxy, 1-methylcyclobutoxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, cyclooctyloxy and the like.
- the "6-14 membered aryl group" as used in the present invention means a cyclic aromatic group having a ring atom of 6 to 14 carbon atoms, and includes a 6-8 membered monocyclic aryl group and a 8-14 membered fused ring aryl group.
- the 6-8 membered monocyclic aryl group means an all-unsaturated aryl group, and specific examples include, but are not limited to, phenyl, cyclooctyltetraenyl and the like.
- the 8-14 membered fused ring aryl group refers to a cyclic group in which two or more ring structures share two adjacent carbon atoms, and at least one ring is a wholly unsaturated aromatic ring.
- 8-14 yuan of all unsaturated fused ring aryl groups specific examples include, but are not limited to: naphthyl, anthracenyl and phenanthryl, etc., and also include 8-14 yuan partially saturated fused ring aryl groups, such as benzo 3-8 yuan A saturated monocyclic cycloalkyl group, a benzo 3-8 member partially saturated monocyclic cycloalkyl group, and specific examples include, but are not limited to: 2,3-dihydro-1H-indenyl, 1H-indenyl, 1,2,3 , 4-tetrahydronaphthyl, 1,4-dihydronaphthyl and the like.
- a 6-10 membered aryl group is preferred, and a benzene or benzo 3-8 member saturated monocyclic cycloalkyl group or a benzo 3-8 member partially saturated monocyclic cycloalkyl group is further preferred.
- the term "6-10 membered aryl” means a specific example in which the number of ring atoms in the above “aryl group” is 6-10.
- the "5-14 membered heteroaryl group” refers to an unsaturated aromatic aromatic group having 5 to 14 ring atoms (having at least one hetero atom), including 5-8 members of heteroaryl. a 6-14 membered heteroaryl group, wherein the hetero atom has nitrogen, oxygen and sulfur, and the like, and includes a carbon atom, a nitrogen atom and a sulfur atom which may be substituted by oxo.
- the 5-8 membered heteroaryl group means an unsaturated aromatic aromatic group having 5 to 8 ring atoms (having at least one hetero atom selected from the group consisting of nitrogen, oxygen and sulfur), preferably 5 to 6 members.
- Heteroaryl specific examples include, but are not limited to, furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, iso-, oxazolyl, oxadiazolyl, imidazolyl, pyridyl Azyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-'oxadiazolyl, 1,2,4-oxadiazolyl, 1,2, 5- ⁇ oxadiazolyl, 1,3,4-3 ⁇ 4 oxadiazolyl, pyridinyl, pyrimidinyl, 1,4-dioxin-yl, 2H-l, 2-3 ⁇ 4 piperazin
- 6-14 membered heteroaryl which means an unsaturated group containing 6 to 14 ring atoms (having at least one hetero atom) which are formed by two or more ring structures sharing two adjacent atoms with each other.
- Aromatic fused ring structure specific examples include, but are not limited to: benzofuranyl, benzisofuranyl, benzothienyl, fluorenyl, benzo, oxazolyl, benzimidazolyl, carbazolyl , benzotriazolyl, quinolyl, isoquinolyl, acridinyl, phenanthryl, benzoxazinyl, pyridazinyl, quinazolinyl, quinoxalinyl, phenolzinyl, acridine Base, fluorenyl, naphthyridyl and the like.
- the "5-membered heteroaryl group” as used in the present invention means a heteroaryl group having 5 ring atoms in the above examples, and specific examples include, but are not limited to, imidazolyl, furyl, thienyl, pyrrolyl, pyrazolyl, Thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3,4-tetrazolyl, 1,2,3,5-tetrazolyl, um Azole, etc., among them, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3,4-tetrazolyl, 1,2,3 , 5-tetrazolyl, oxazole and thienyl.
- the "3-14 membered heterocyclic group" as used in the present invention means a 3-14 membered cyclic group containing one to more hetero atoms, and includes a saturated, partially saturated, unsaturated 3-8 membered monoheterocyclic group and A 5-14 membered fused heterocyclic group having nitrogen, oxygen, sulfur, and the like, and including a carbon atom, a nitrogen atom, and a sulfur atom may be substituted by oxo. Also included are the heteroaryl groups mentioned above and their dihydrogenated and tetrahydrogenated analogs.
- 5-14 membered fused heterocyclic group means 5-14 fused ring groups formed by two or more ring structures sharing two adjacent atoms, including saturated, partially saturated, unsaturated A heterocyclic ring containing a hetero atom, a spiro ring, or a bridge ring.
- a 3-8 membered monoheterocyclic group means a monocyclic heterocyclic group having 3 to 8 ring atoms (having at least one hetero atom), and includes a 3-8 membered unsaturated monoheterocyclic group and a 3-8 membered moiety. Saturated monoheterocyclic group, 3-8 membered saturated monoheterocyclic group.
- the 3-8 membered unsaturated monoheterocyclic group means an aromatic hetero atom-containing cyclic group, and specific examples include, but are not limited to, furyl, thienyl, pyrrolyl, thiazolyl, thiadiazolyl, oxazole Base, oxadiazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, 1,4-dioxadienyl, 2H-U-methylazinyl, 4H-U-oxazinyl, 6 /7-1,2-,azinyl, 4H-U-oxazinyl, 6H-1,3-oxazinyl, 4H-1,4-oxazinyl, pyridazinyl, pyrazinyl, 1,2 ,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,4,5-tetraazinyl
- the 3-8 membered partially saturated monoheterocyclic group refers to a cyclic group containing a double bond and a hetero atom, and specific examples include, but are not limited to, 2,5-dihydrothienyl, 4,5-dihydropyrazolyl, 3,4-Dihydro-2H-pyranyl, 5,6-dihydro-4H-l, 3-azinyl and the like.
- 3-8-membered saturated monoheterocyclic group means All of the hetero atom-containing cyclic groups which are saturated bonds, and specific examples include, but are not limited to, aziridine, azetidinyl, thietane, tetrahydrofuranyl, tetrahydropyrrolyl, imidazole Alkyl, pyrazolidinyl, tetrahydrofuranyl, 1,4-dioxanyl, 1,3-dioxanyl, 1,3-dithianyl, morpholinyl , piperazinyl and the like.
- a 5- to 6-membered heterocyclic group is preferred, and is a group of 5 to 6 ring atoms in the above examples.
- the heterocyclic ring containing a hetero atom, a spiro ring, or a bridged ring specifically refers to a 6-14 membered heterocyclic group formed by replacing a non-common carbon atom in a ring, a spiro ring, or a bridge ring with a hetero atom. 5-12-membered spiroheterocyclyl, 5-12-membered bridged heterocyclic group.
- 6-14-membered heterocyclic group means a cyclo-ring structure in which 6 to 14 ring atoms (having at least one hetero atom) are bonded by two or more ring structures sharing two adjacent atoms with each other. And includes a 6-14 membered unsaturated heterocyclic group, a 6-14 membered partially saturated heterocyclic group, and a 6-10 membered saturated heterocyclic group.
- 6-14-membered unsaturated heterocyclic group means a structure in which all rings are unsaturated, such as a benzo 3-8-unsaturated monoheterocyclic group, and a 3-8-membered unsaturated mono-hybrid.
- the structure and the like formed by a cyclic group and a 3-8 membered unsaturated monoheterocyclic group and specific examples thereof include, but are not limited to, - benzofuranyl, benzoisofuranyl, benzothienyl, fluorenyl, benzoxazolyl , benzimidazolyl, oxazolyl, benzotriazolyl, quinolyl, isoquinolyl, acridinyl, phenanthridine, oxazolinyl, quinoxalinyl, phenolazine, acridine Base, sulfhydryl, naphthyridyl, Mission and so on.
- the 6-14 membered partially saturated heterocyclic group refers to a fused ring structure containing at least one partially saturated ring, such as a structure formed by a benzo 3-8-membered partially saturated monoheterocyclic group, and a 3-8-membered partially saturated monocyclic ring.
- a structure in which a 3-8-membered partially saturated monoheterocyclic group is formed, and the like, and specific examples include, but are not limited to, 1,3-dihydrobenzofuranyl, benzo1.3]dioxolyl, isoindole Olinyl group,
- a 6-10 membered saturated heterocyclic group refers to a structure in which all of the rings are saturated fused ring structures, such as a 3-8-membered saturated monoheterocyclic group and a 3-8-membered saturated monoheterocyclic group, and specific examples thereof Hydropyrrolyl, cyclopentahydrotetrahydropyrrolyl, azetidinazolidinyl,
- the cyclic group structure replaces a group formed by any substitutable hydrogen atom.
- a 5-12-membered bridged heterocyclic group means a bridged ring "5-12-membered bridged heterocyclic group" formed by 5 to 12 ring atoms (having at least one hetero atom) including a 5-12-membered saturated bridged heterocyclic group. , 5-12 yuan partially saturated bridge heterocyclic group.
- a 5-12-membered saturated bridge heterocyclic group refers to a cyclic group in which all of the rings in the heterocyclic ring are saturated, preferably 7-8.
- the cyclic 12-membered partially saturated bridged heterocyclic group of the ring-shaped structure substituted with any substitutable hydrogen atom means that at least one ring in the bridged heterocyclic ring is unsaturated.
- the group is preferably a 7-8 membered partially saturated bridged heterocyclic group, and specific examples include, but are not limited to:
- the 5-12 membered spiroheterocyclyl group means a spiro ring structure formed by 5 to 12 ring atoms (having at least one hetero atom).
- the 5-12 membered spiroheterocyclyl group includes a 5-12 membered saturated spiroheterocyclyl group and a 5-12 membered partially saturated spiroheterocyclic group.
- the cyclic group structure replaces a group formed by any substitutable hydrogen atom.
- the 5-12 membered partially saturated spiroheterocyclyl group means that at least one of the spiroheterocycles is an unsaturated cyclic group.
- Specific examples include but are not limited to:
- the cyclic group structure replaces a group formed by any substitutable hydrogen atom.
- 3-8 membered heterocyclic group, 5-7 membered heterocyclic group or 5-6 membered heterocyclic group means that the number of ring atoms in the above "3-14 membered heterocyclic group" is 3-8 yuan, 5-8 yuan, 5 Specific examples of -7 yuan, 5-6 yuan.
- the "3-8 membered cyclic group” as used in the present invention means a 3-8 membered saturated or unsaturated carbocyclic group or a saturated or unsaturated heterocyclic group containing a hetero atom, including a 3-8 membered saturated carbon. a cyclic group and a 3-8 membered unsaturated carbocyclic group, and a 3-8 membered heterocyclic saturated heterocyclic group and a 3-8 membered hetero atom containing unsaturated heterocyclic group, as described in the present invention
- the "5-6 membered cyclic group” means a specific example containing 5 to 6 ring atoms. among them:
- the "3-8 membered saturated carbocyclic group” means a 3-8 membered cycloalkyl group, and specific examples include, but are not limited to, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctyl a group such as a cyclopropyl group, a cyclopentyl group, a cyclohexane group or the like, more preferably a cyclopentyl group or a cyclohexane group;
- the "3-8 member unsaturated carbocyclic group” means a 3-8 membered cyclic group containing an unsaturated double bond, and specific examples include, but are not limited to, cyclopropene, cyclobutene, cyclopentene, cyclohexene, a cyclopentadiene, a cyclohexadiene, a cycloheptadiene, a cyclooctadiene group or the like; wherein, preferably, a cyclopentene, a cyclohexene, a cyclopentadiene, a cyclohexadienyl group or the like; more preferably a ring; Pentenyl, cyclopentadienyl;
- the "3-8 membered saturated heterocyclic group containing a hetero atom” means a cyclic group having 3 to 8 ring atoms (having at least one hetero atom), and specific examples include, but are not limited to: aziridine, nitrogen Heterocyclic butane, 1,2-diazetidine, pyrrolidine, imidazolidine, pyrazolidine, hydrogenated pyridone, piperidine, piperazine, ethylene oxide, thietane, oxetane Alkane, 1,2-dioxetane, thietane, tetrahydrofuran, tetrahydrothiophene, 1,3-dioxolane, 1,3-dithiolane, tetrahydropyridinium , 1,4-dioxane, 1,3-dioxane, 1,3-oxathiane, oxazolidine, morpholyl group, etc.; Cyclopropan
- the "3-8 member unsaturated heterocyclic group containing a hetero atom” means 3-8 (including at least one hetero atom) heterocyclic group in which an unsaturated bond is present in the ring, and specific examples include, but are not limited to, a nitrogen hetero ring Butadiene, 1,2-diazacyclobutene, B-pyrrol, 4,5-dihydropyrrole, 2,5-dihydropyrrole, imidazole, 4,5-dihydroimidazole, pyrazole, 4, 5-dihydropyrazole, 1,2,3-triazole, 1,2,4-triazole, pyridine, 2-pyridone, 4-pyridone, pyridazine, pyrimidine, pyrazine, 1,2,3 - triazine, 1,2,4-triazine, azepanes, 1,2-diazepine, 1,3-diazacyclocycle Heptane, 1,4-diazepine, aza
- pyrrole dihydropyrrole, imidazole, 4,5-dihydroimidazole, pyrazole, 4,5-dihydropyrazole, pyridine, pyridazine, pyrimidine, pyrazine, furan, thiophene, 2,5-dihydrol Thiophene, 2H-pyran, 2H-pyran-2-one, 3,4-dihydro-2H-pyran, 4H-pyran, 4H-pyran-4-one, 1,4-dioxole Hexadiene, 1,4-dithiahexadiene, 1,4-oxethiohexadiene, oxazole, 4,5-dihydro-conazole, azole, iso-oxazole, 4,5- Dihydroisoxazole, 2,3-dihydroisoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, thi
- the "5-6 membered saturated or unsaturated nitrogen heterocyclic group” as used in the present invention means a cyclic group having 5 to 6 ring atoms (including at least one hetero atom nitrogen) in the above examples, and specific examples Including but not limited to: pyrrolyl, tetrahydropyrrolyl, imidazolidinyl, pyrazolidinyl, imidazolyl, pyrazolyl, 4,5-dihydropyrazole, 1,2,3-triazolyl, 1 , 2,4-triazolyl, 1,2,3,4-tetrazolyl, 1,2,3,5-tetrazolyl, pyridyl, piperidinyl, pyridazinyl, pyrimidinyl, Pyrazinyl, piperazinyl, piperazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,4,5-tetraazinyl,
- the parallel fused bicyclic system includes, but Not limited to, 2,3-dihydro-1H-indenyl, porphyrinyl, naphthyl, 1,2,3,4-tetrahydro-quinolinyl, 1,2,3,4-tetrahydro-iso Quinolinyl, isoindolyl, fluorenyl, isodecyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, 2,3-dihydro-benzothienyl, benzo Thienyl, benzothiazolyl, 2,3-dihydro-benzofuranyl, benzofuranyl, benzoxazolyl, 1,2,3,4-tetra
- a parallel fused bicyclic system composed of an anthracene ring and an anthracene ring, including, but not limited to, the following: (1) When the anthracene ring is a benzene ring, the two shared atoms of the anthracene ring and the anthracene ring are carbon atoms. (2) When the B ring is a 5-membered heteroaryl ring, the two shared atoms of the A ring and the B ring may be carbon atoms or two shared atoms, at least one of which is a hetero atom, preferably a nitrogen atom. Particularly preferred compounds include :
- the invention also provides a preparation method of the above compound : reaction equation:
- Reaction step raw material 1, raw material 2, inorganic base (such as cesium carbonate, potassium carbonate, etc.) and palladium catalyst (such as
- Reaction step raw material 1, raw material 2, alkali (such as potassium t-butoxide) and a palladium catalyst (such as Pd 2 (dba) 3 , Pd (dba) 2 , etc.) are dissolved in toluene, and heated to reflux until the starting material disappears. The solvent was evaporated to dryness, and the solid was separated and purified on silica gel column to give the compound.
- alkali such as potassium t-butoxide
- a palladium catalyst such as Pd 2 (dba) 3 , Pd (dba) 2 , etc.
- the raw materials 1 and 2 in the above reaction equation are all obtained by converting a readily available raw material through a simple functional group.
- RR 2 , R 3 , RR 5 , R 6 , A or B in the above reaction equation are as defined above.
- a “pharmaceutically acceptable salt” of a compound of the invention refers to a base or acid addition salt of a compound of the invention with a pharmaceutically acceptable, non-toxic base or acid, including organic acid salts, inorganic acid salts, Organic alkali salt, inorganic alkali salt.
- Organic acid salts include formates, acetates, propionates, besylate, benzoates, p-toluenesulfonates, 2,3-dihydroxysuccinates, camphorsulfonates, citric acid Salt, methanesulfonate, ethanesulfonate, propanesulfonate, fumarate, gluconate, glutamate, isethionate, lactate, maleate, malate , mandelic acid salt, mucic acid salt, pamoate, pantothenate, succinate, tartrate, etc., particularly preferably benzoate, benzenesulfonate, p-toluenesulfonate, methanesulfonate, Citrate, maleate, fumarate, tartrate.
- the inorganic acid salt includes a hydrochloride, a hydrobromide, a hydroiodide, a sulfate, a phosphate, a nitrate, etc., and particularly preferably a hydrochloride, a hydrobromide, a sulfate, or a phosphate.
- the organic base salt includes an amine salt including a salt formed with primary, secondary and tertiary amines, a cyclic amine and an alkali ion exchange resin, and may be selected from salts formed with the following organic bases: for example, arginine, betaine, caffeine, gall Base, hydrazine, ⁇ '-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethyl Alcohol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, meglumine, glucosamine, histidine, seabamin, isopropylamine, lysine, methyl gluco Glucamine, morpholine, piperazine, piperidine, procaine, guanidine, theobromine, triethylamine, trimethylamine, tripropylamine and tromethamine.
- organic bases for example, argin
- Inorganic alkali salts include salts with ammonia, alkali metals, alkaline earth metals, such as ammonium salts, and lithium, sodium, potassium, calcium, magnesium, zinc, barium, aluminum, iron, copper,
- the ferrous salt, the manganese salt, and the divalent manganese salt are particularly preferably an ammonium salt, and a sodium salt, a potassium salt, a calcium salt, and a magnesium salt.
- the compound of the formula (I) of the present invention forms a phosphate with phosphoric acid and further forms a metal phosphate of a compound of the formula (I), such as a phosphate disodium salt, with a metal salt.
- a "prodrug" of a compound of the invention refers to a compound (referred to as the original drug) which can be converted to any of the compounds of formula (I) or to a pharmaceutically acceptable salt of a compound of formula (I) under physiological conditions or by solvolysis.
- the prodrug When administered to a patient, the prodrug may be inactive, but it is converted to the active compound in vivo.
- the compound of the formula (I) of the present invention has a hydroxyl group, it can form an ester type prodrug with an amino acid, a phosphoric acid or the like, and the prodrug is stable in water or an acid solution, and dissociates to form a free form by action of an esterase or a phosphatase in the blood.
- Compound Compound.
- the prodrug of the compound of the formula (I) of the present invention has more excellent solubility than the original drug, is more easily absorbed by a passive object or a human body, is better converted into a prodrug compound in the blood, and exerts an antibacterial activity.
- the "isomer" of the compound of the present invention means a compound having the same chemical formula and a different structure, including conformational isomers (structural isomers) and stereoisomers (configurational isomers) and the like. Structural heterogeneity is further divided into (carbon) chain isomerism, positional isomerization, and functional group isomerization (heterologous isomerism).
- Stereoisomerism is further divided into conformational and conformational isomerism, while conformational isomerism is also divided into cis-trans isomerization and optical isomerism.
- “Stereoisomer” means when the compound of the invention contains one or more asymmetric centers and thus acts as a racemate and a racemic mixture, a single enantiomer, a mixture of diastereomers and a single Diastereomers.
- the compounds of the invention have asymmetric centers, each of which will independently produce two optical isomers, the scope of the invention including all possible optical isomers and mixtures of diastereomers and pure or partially Pure compound.
- the present invention includes a cis isomer and a trans isomer unless otherwise specified.
- the compounds of the present invention may exist in tautomeric forms which have different hydrogen attachment points by displacement of one or more double bonds. Each tautomer and mixtures thereof are included in the compounds of the invention.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the formula (I) of the present invention, or a pharmaceutically acceptable salt thereof, an isomer thereof or a prodrug thereof, and one or more pharmaceutically acceptable substances Carrier and/or diluent.
- the composition may be formulated into any of the clinically or pharmaceutically acceptable dosage forms, preferably oral preparations and injections.
- the compound of the present invention or a pharmaceutically acceptable salt thereof, an isomer thereof or a prodrug thereof can be administered to a mammal by oral, parenteral (intravenous, intramuscular, subcutaneous or rectal), topical administration or the like.
- a mammal for example, people.
- the compound of the present invention is used in an amount ranging from about 0.1 to 100 mg/kg body weight per day, for example, 3 to 50 mg/kg body weight per day.
- the compound of the present invention or a pharmaceutically acceptable salt thereof, an isomer thereof or a prodrug thereof may be formulated into an injection, including for intramuscular injection, intravenous injection, intravenous drip, subcutaneous A sterile solution type, emulsion type, dispersion type or suspension type preparation for injection or the like, and a sterile powder or concentrated solution for injection which is prepared or diluted into a solution, a dispersion or a suspension before use.
- the injection can be produced by a conventional method in the field of the prior art, and an optional aqueous solvent or a non-aqueous solvent can be used.
- aqueous solvent is water for injection, and 0.9% sodium chloride solution or other suitable aqueous solution may also be used;
- the commonly used non-aqueous solvent is vegetable oil, for example, soybean oil for injection, and others, such as ethanol, propylene glycol, polyethylene glycol, etc. Aqueous solution, etc.
- additives may not be added, and appropriate additives may be added according to the nature of the drug, such as osmotic pressure regulators, pH adjusters, solubilizers, fillers, antioxidants, bacteriostatic agents, emulsifiers, suspending agents. Agents, etc.
- Commonly used osmotic pressure adjusting agents include sodium chloride, glucose, potassium chloride, magnesium chloride, calcium chloride, sorbitol, etc., preferably sodium chloride or glucose; commonly used pH adjusting agents include acetic acid - sodium acetate, lactic acid, hydrazine Acid-sodium citrate, sodium bicarbonate-sodium carbonate, etc.; commonly used solubilizing agents include polysorbate 80, propylene glycol, lecithin, polyoxyethylene castor oil, etc.; commonly used fillers include lactose, mannitol, sorbitol, Dextran anhydride; commonly used antioxidants are sodium sulfite, sodium bisulfite, sodium metabisulfite, etc.; commonly used bacteriostatic agents are phenol, cresol, chlorobutanol and the like.
- the pharmaceutical composition may also be formulated in a conventional manner for rectal or topical administration, including suppositories.
- the compound of the present invention or a pharmaceutically acceptable salt thereof, an isomer thereof or a prodrug thereof can be formulated into a conventional solid preparation such as a tablet, a capsule, a pill or a granule by a conventional method.
- Oral liquid preparations such as oral solutions, oral suspensions, sugars, and the like.
- the tablets are mainly oral tablets, and include tablets, sublingual tablets, oral patches, chewable tablets, dispersible tablets, soluble tablets, effervescent tablets, sustained release tablets, controlled release tablets and enteric coated tablets.
- Capsules can be classified into hard capsules, soft capsules, sustained release capsules, controlled release capsules and enteric capsules according to their dissolution and release characteristics.
- Pills include dropping pills, sugar pills, pellets, and the like.
- Granules can be classified into soluble granules, suspended granules, effervescent granules, enteric granules, sustained release granules, and controlled release granules.
- a suitable filler, binder, disintegrator, lubricant or the like may be added.
- Commonly used fillers include starch, powdered sugar, calcium phosphate, calcium sulfate dihydrate, dextrin, microcrystalline cellulose, lactose, pregelatinized starch, mannitol, etc.
- commonly used binders include sodium carboxymethyl cellulose, PVP -K30, hydroxypropyl cellulose, starch, methyl cellulose, ethyl cellulose, hypromellose, gelatinized starch, etc.
- commonly used disintegrants include kilo starch, crospovidone, cross-linked carboxy Methylcellulose sodium, sodium carboxymethyl starch, low-substituted hydroxypropylcellulose, etc.
- commonly used lubricants include magnesium stearate, talc, sodium lauryl sulfate, micronized silica gel, and the like.
- the present invention provides the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, or an isomer thereof or a prodrug thereof, for the manufacture of a medicament for the treatment and/or prevention of an infectious disease.
- the present invention provides a method of treating and/or preventing an infectious disease comprising administering a compound of the formula (I) of the present invention, or a pharmaceutically acceptable salt thereof, an isomer thereof or a prodrug thereof, in need thereof A mammal that is treated or prevented, such as a human.
- the compounds of the present invention have good antibacterial activity and are useful for the treatment and/or prevention of various infectious diseases.
- the oxazolidinone antibiotic of the invention has good antibacterial activity against Gram-positive bacteria, and also has good antibacterial activity against Gram-positive resistant bacteria, and can be used for treating and/or preventing caused by Gram-positive bacteria.
- Various diseases include:
- Test strains The following clinical isolates were purchased at public institutions.
- Methicillin-resistant Staphylococcus aureus MRSA
- methicillin-resistant Staphylococcus epidermidis MRSE
- methicillin-sensitive Staphylococcus aureus MSSA
- methicillin-sensitive Staphylococcus epidermidis MSSE
- Enterococcus faecalis Efa
- Enterococcus faecium efm
- Streptococcus pneumoniae Methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE), methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-sensitive Staphylococcus epidermidis (MSSE), Enterococcus faecalis ( Efa), Enterococcus faecium (efm), Streptococcus pneumoniae.
- Source Qianfoshan Hospital, Yunnan First People's Hospital, Shanghai
- the compound of the present invention has good antibacterial activity against the above test strains, and the antibacterial activity of some compounds is superior to that of the listed drugs, and the antibacterial activity is comparable or better than that of the comparative compound 38 group.
- the compounds of the invention have good clinical application potential.
- Benzyl 4-bromo-3-fluorophenylcarbamate (20 g, 61.7 mmol) was dissolved in 180 mL THF and cooled to -78 V.
- LiHMDS (1.0M in THF, 62.4 mL, 62.4 mmol)
- i?-glycidyl butyrate (2.21 mL, 62.3 mmol) was added dropwise, and the reaction was continued at low temperature for 1 h and then raised to room temperature for 60 h. Quenched with saturated ammonium chloride, water was added andEtOAc was evaporated.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/347,595 US9487545B2 (en) | 2011-09-30 | 2012-09-29 | Fused ring-containing oxazolidinones antibiotics |
JP2014532236A JP5833764B2 (ja) | 2011-09-30 | 2012-09-29 | 縮合環を有するオキサゾリドン(oxazolidone)類の抗菌物質 |
EP12837499.8A EP2762480A4 (en) | 2011-09-30 | 2012-09-29 | OXAZOLIDINONIBIOTICS WITH CONDENSED RINGS |
HK14112747.5A HK1199249A1 (zh) | 2011-09-30 | 2014-12-19 | 含有並環的噁唑烷酮類抗菌素 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110291417.4 | 2011-09-30 | ||
CN201110291417 | 2011-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013044865A1 true WO2013044865A1 (zh) | 2013-04-04 |
Family
ID=47994281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2012/082422 WO2013044865A1 (zh) | 2011-09-30 | 2012-09-29 | 含有并环的噁唑烷酮类抗菌素 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9487545B2 (zh) |
EP (1) | EP2762480A4 (zh) |
JP (1) | JP5833764B2 (zh) |
CN (1) | CN103030634B (zh) |
HK (1) | HK1199249A1 (zh) |
WO (1) | WO2013044865A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016041508A1 (zh) * | 2014-09-17 | 2016-03-24 | 博瑞生物医药技术(苏州)有限公司 | 一种噁唑烷酮类化合物及其中间体的制备方法 |
WO2017158381A1 (en) * | 2016-03-18 | 2017-09-21 | Mission Therapeutics Limited | 4,6 dihydropyrrolo [3,4-c] pyrazole-5 (1h)-carbonitrile derivates for trating cancer |
WO2020021468A1 (en) | 2018-07-25 | 2020-01-30 | Cadila Healthcare Limited | Substituted oxazolidinones for the treatment of mammalian infections |
WO2020234636A1 (en) | 2019-05-17 | 2020-11-26 | Cadila Healthcare Limited | Novel compounds for the treatment of mammalian infections |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013044865A1 (zh) | 2011-09-30 | 2013-04-04 | 山东轩竹医药科技有限公司 | 含有并环的噁唑烷酮类抗菌素 |
CN104177373A (zh) * | 2013-05-22 | 2014-12-03 | 中国医学科学院医药生物技术研究所 | 抗结核化合物imb-cc223 |
CN105418678B (zh) * | 2014-09-17 | 2018-11-20 | 正大天晴药业集团股份有限公司 | 一种磷酸特地唑胺的制备方法 |
CN105837633B (zh) * | 2015-01-12 | 2018-11-20 | 正大天晴药业集团股份有限公司 | 一种抗菌化合物的制备方法 |
CN105503955B (zh) * | 2014-10-15 | 2018-11-20 | 正大天晴药业集团股份有限公司 | 一种抗革兰氏阳性菌的化合物的制备方法 |
CN105566392B (zh) * | 2014-10-15 | 2018-12-21 | 正大天晴药业集团股份有限公司 | 一种细菌蛋白质合成抑制剂的制备方法 |
CN106045934A (zh) * | 2015-10-27 | 2016-10-26 | 博瑞生物医药(苏州)股份有限公司 | 一种合成泰地唑胺的中间体的晶型 |
GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
KR102618946B1 (ko) * | 2017-03-27 | 2023-12-29 | 하이드로-퀘벡 | 전해질 조성물에서 또는 전극 첨가제로서 사용하기 위한 염 |
CN111349059B (zh) * | 2018-12-20 | 2023-03-31 | 中国科学院上海药物研究所 | 一类手性环氧化合物的制备方法 |
CN112047937B (zh) * | 2019-06-06 | 2023-04-07 | 劲方医药科技(上海)有限公司 | 四氢吡啶并[3,4-d]嘧啶-2(1H)-酮类化合物,其制法与医药上的用途 |
EP4005638A4 (en) | 2019-07-29 | 2023-07-05 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001042242A1 (en) * | 1999-08-12 | 2001-06-14 | Ortho-Mcneil Pharmaceutical, Inc. | Antibacterial heterobicyclic substituted phenyl oxazolidinones |
WO2009157423A1 (ja) * | 2008-06-24 | 2009-12-30 | 財団法人乙卯研究所 | 縮合環を有するオキサゾリジノン誘導体 |
WO2011097946A1 (zh) * | 2010-02-11 | 2011-08-18 | 山东轩竹医药科技有限公司 | 含有并环稠合双环的噁唑烷酮化合物及其制备和应用 |
CN102190656A (zh) * | 2010-03-16 | 2011-09-21 | 山东轩竹医药科技有限公司 | 含有五元杂环的噁唑烷酮抗菌素 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2218088A1 (en) * | 1995-05-11 | 1996-11-14 | Pharmacia & Upjohn Company | Spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones |
US6608081B2 (en) | 1999-08-12 | 2003-08-19 | Ortho-Mcneil Pharmaceutical, Inc. | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods |
WO2002064574A2 (en) | 2001-02-07 | 2002-08-22 | Ortho-Mcneil Pharmaceutical, Inc. | Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods |
JP5161070B2 (ja) | 2006-03-31 | 2013-03-13 | 財団法人乙卯研究所 | ヘテロ環を有する新規化合物 |
WO2013044865A1 (zh) | 2011-09-30 | 2013-04-04 | 山东轩竹医药科技有限公司 | 含有并环的噁唑烷酮类抗菌素 |
-
2012
- 2012-09-29 WO PCT/CN2012/082422 patent/WO2013044865A1/zh active Application Filing
- 2012-09-29 EP EP12837499.8A patent/EP2762480A4/en not_active Withdrawn
- 2012-09-29 JP JP2014532236A patent/JP5833764B2/ja not_active Expired - Fee Related
- 2012-09-29 US US14/347,595 patent/US9487545B2/en not_active Expired - Fee Related
- 2012-09-29 CN CN201210394989.XA patent/CN103030634B/zh active Active
-
2014
- 2014-12-19 HK HK14112747.5A patent/HK1199249A1/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001042242A1 (en) * | 1999-08-12 | 2001-06-14 | Ortho-Mcneil Pharmaceutical, Inc. | Antibacterial heterobicyclic substituted phenyl oxazolidinones |
WO2009157423A1 (ja) * | 2008-06-24 | 2009-12-30 | 財団法人乙卯研究所 | 縮合環を有するオキサゾリジノン誘導体 |
US20110098471A1 (en) | 2008-06-24 | 2011-04-28 | Issei Katoh | Oxazolidinone derivative having fused ring |
WO2011097946A1 (zh) * | 2010-02-11 | 2011-08-18 | 山东轩竹医药科技有限公司 | 含有并环稠合双环的噁唑烷酮化合物及其制备和应用 |
CN102190656A (zh) * | 2010-03-16 | 2011-09-21 | 山东轩竹医药科技有限公司 | 含有五元杂环的噁唑烷酮抗菌素 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2762480A4 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016041508A1 (zh) * | 2014-09-17 | 2016-03-24 | 博瑞生物医药技术(苏州)有限公司 | 一种噁唑烷酮类化合物及其中间体的制备方法 |
WO2017158381A1 (en) * | 2016-03-18 | 2017-09-21 | Mission Therapeutics Limited | 4,6 dihydropyrrolo [3,4-c] pyrazole-5 (1h)-carbonitrile derivates for trating cancer |
WO2020021468A1 (en) | 2018-07-25 | 2020-01-30 | Cadila Healthcare Limited | Substituted oxazolidinones for the treatment of mammalian infections |
WO2020234636A1 (en) | 2019-05-17 | 2020-11-26 | Cadila Healthcare Limited | Novel compounds for the treatment of mammalian infections |
Also Published As
Publication number | Publication date |
---|---|
JP5833764B2 (ja) | 2015-12-16 |
CN103030634A (zh) | 2013-04-10 |
HK1199249A1 (zh) | 2015-06-26 |
CN103030634B (zh) | 2015-07-15 |
EP2762480A1 (en) | 2014-08-06 |
JP2014530207A (ja) | 2014-11-17 |
US20140243288A1 (en) | 2014-08-28 |
US9487545B2 (en) | 2016-11-08 |
EP2762480A4 (en) | 2015-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013044865A1 (zh) | 含有并环的噁唑烷酮类抗菌素 | |
AU2018257203B2 (en) | Novel tetrahydronaphthyl urea derivatives | |
WO2019205983A1 (zh) | 氧杂螺环类化合物及其制备方法和用途 | |
TW200906825A (en) | Inhibitors of protein kinases | |
JP6860237B2 (ja) | インドールアミン2,3−ジオキシゲナーゼ阻害剤及び適用 | |
CN115151541A (zh) | 新型化合物及其用途 | |
JP5796134B2 (ja) | ビアリールヘテロ環で置換されたオキサゾリドン抗菌薬 | |
JP2024509997A (ja) | 抗菌化合物 | |
JP2024509998A (ja) | 抗菌化合物 | |
WO2022083703A1 (en) | Compounds and compositions for treating conditions associated with lpa receptor activity | |
BR112014018763B1 (pt) | Sais de adição de ácido cristalino de um derivado tricíclico ou hidratos dos mesmos e método de produção dos mesmos | |
WO2022037631A1 (zh) | 杂环类衍生物及其制备方法和用途 | |
CN103709102A (zh) | 含有螺环的截短侧耳素类抗生素 | |
ES2409536B1 (es) | Quinonas heterocíclicas sintéticas con actividad antimicrobiana. | |
OA20727A (en) | Novel compounds and their use. | |
CN115124524A (zh) | 三环类衍生物及其制备方法和用途 | |
TWI313602B (en) | Gyrase inhibitors and uses thereof | |
CN110878052A (zh) | 一种含有fxr激动剂的化合物及其制备方法和应用 | |
JP2000302760A (ja) | 2−メルカプトキノリン誘導体 | |
JP2019182805A (ja) | リンカー部位を持つ縮環ピラゾール誘導体およびその医薬用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12837499 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14347595 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012837499 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014532236 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |